Biogen (California)
3030 Callan Road
San Diego
California
92121
United States
Tel: 858-431-8500
Fax: 858-431-8750
Website: http://www.biogen.com/
146 articles about Biogen (California)
-
Regulus Therapeutics, Inc. Enters Into New Collaboration Agreement With Biogen Idec, Inc. (California) To Identify Microrna Biomarkers In Multiple Sclerosis
8/5/2014
-
Biogen Idec, Inc. (California) Signs License Agreement With Amunix, Inc. For XTENylated Factor VIII
4/21/2014
-
George A. Scangos, Ph.D., Of Biogen Idec, Inc. (California) To Join Agilent Technologies Inc. Board Of Directors
3/20/2014
-
Sangamo BioSciences, Inc. Announces Conference Call And Webcast To Discuss Global Collaboration With Biogen Idec, Inc. (California) To Develop Treatments For Hemoglobinopathies
1/9/2014
-
Regulus Therapeutics, Inc. Demonstrates Initial Progress In microRNA Biomarkers MS Collaboration And Receives Milestone Payment From Biogen Idec, Inc. (California)
11/20/2013
-
Isis Pharmaceuticals, Inc. Earns $3.5 Million From Biogen Idec, Inc. (California)
5/10/2013
-
Not in Genentech's Shadow Anymore, Biogen Idec, Inc. (California) Makes Huge Comeback in Biotech
12/6/2012
-
Sunesis Pharmaceuticals, Inc. Receives $1.5 Million Milestone Payment from Biogen Idec, Inc. (Massachusetts) Related to Kinase Inhibitor Program
6/27/2012
-
Swedish Orphan Biovitrum's Agreement With Biogen Idec, Inc. (Massachusetts) Regarding Long-Lasting rFVIIIFc and rFIXFc Hemophilia Programs
2/6/2012
-
Burrill & Company Advises Samsung Corporation in Biosimilars Joint Venture Agreement With Biogen Idec, Inc. (California)
12/7/2011
-
Biogen Idec, Inc. (California) and Swedish Orphan Biovitrum Present Data on Long-Lasting Recombinant Factor VIII Therapy at International Society on Thrombosis and Haemostasis Meeting
7/26/2011
-
Biogen Idec, Inc. (California) Receives Approval in the European Union for AVONEX(R) PEN(TM)
6/7/2011
-
Biogen Idec, Inc. (California) to Present at the Bank of America Merrill Lynch 2011 Healthcare Conference
5/5/2011
-
Amunix, Inc. Signs Research Collaboration With Biogen Idec, Inc. (California) for Next Generation Long-Lasting Blood Factor Products
4/13/2011
-
Biogen Idec, Inc. (California) to Name CEO in Coming Weeks; COO to Exit
6/8/2010
-
Roche Holding AG And Biogen Idec, Inc. (California)'s Rituxan Halves Risk Of Lymphoma Recurrence According to Phase III Study
5/21/2010
-
Patent Complaint Filed Against GlaxoSmithKline, Genmab A/S Drug Arzerra By Biogen Idec, Inc. (California) And Roche
3/25/2010
-
IPS Congratulates Biogen Idec, Inc. (California) on Winning the 2010 Facility of the Year Award for Operational Excellence
1/20/2010
-
Biogen Idec, Inc. (California) to Provide Business Update at Investor Meeting
1/12/2010
-
Facet Biotech's Board of Directors Reiterates Recommendation That Stockholders Not Tender at $17.50 per Share To Biogen Idec, Inc. (California)
12/16/2009